A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered

- Jackson, Evangeline R., Persson, Mika L., Fish, Cameron J., Findlay, Izac J., Mueller, Sabine, Nazarian, Javad, Hulleman, Esther, van der Lugt, Jasper, Duchatel, Ryan J., Dun, Matthew D.

Diffuse midline glioma, H3K27-altered: illuminating the dark side of the moon

- Dun, Matthew D., Odia, Yazmin, Arrillaga-Romany, Isabel

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

- Duchatel, Ryan J., Jackson, Evangeline R., Kearney, Padraic S., Jamaluddin, M. Fairuz B., Douglas, Alicia M., Beitaki, Tyrone, McEwen, Holly P., Persson, Mika L., Hocke, Emily A., Jain, Vaibhav, Aksu, Michael, Manning, Elizabeth E., Parackal, Sarah G., Murray, Heather C., Verrills, Nicole M., Hua, Susan, Cairns, Murray J., Alvaro, Frank, Dayas, Christopher V., Dun, Matthew D., Hua, S, de Bock, CE, Colino-Sanguino, Y, Kiltschewskij, Dylan, Valdes-Mora, F, Tsoli, M, Ziegler, DS, Cairns, MJ, Raabe, EH, Vitanza, NA, Hulleman, E, Phoenix, TN, Koschmann, C, Alvaro, F, Findlay, Izac J., Dayas, CV, Tinkle, CL, Wheeler, H, Whittle, JR, Eisenstat, DD, Firestein, R, Mueller, S, Valvi, S, Hansford, JR, Ashley, DM, Mannan, Abdul, Gregory, SG, Kilburn, LB, Nazarian, J, Cain, JE, Dun, MD, Staudt, Dilana E., Thomas, Bryce C., Germon, Zacary P., Laternser, Sandra

Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways

- Venneti, Sriram, Kawakibi, Abed Rahman, Ramage, Samuel, Chi, Andrew, Wen, Patrick Y., Arrillaga-Romany, Isabel, Batchelor, Tracy T., Butowski, Nicholas A., Sumrall, Ashley, Shonka, Nicole, Harrison, Rebecca A., de Groot, John, Ji, Sunjong, Mehta, M, Hall, MD, Daghistani, D, Cloughesy, TF, Ellingson, BM, Beccaria, K, Varlet, P, Kim, MM, Umemura, Y, Garton, H, Waszak, Sebastian M., Franson, A, Schwartz, J, Jain, R, Kachman, M, Baum, H, Burant, CF, Mottl, SL, Cartaxo, RT, John, V, Messinger, D, Sweha, StefanR, Qin, T, Peterson, E, Sajjakulnukit, P, Ravi, K, Waugh, A, Walling, D, Ding, Y, Xia, Z, Schwendeman, A, Hawes, D, Mota, Mateus, Yang, F, Judkins, AR, Wahl, D, Lyssiotis, CA, de la Nava, D, Alonso, MM, Eze, A, Spitzer, J, Schmidt, SV, Duchatel, Ryan J., Pun, Matthew, Dun, Matthew D., Cain, JE, Jiang, L, Stopka, SA, Baquer, G, Regan, MS, Filbin, MG, Agar, NYR, Zhao, L, Kumar-Sinha, C, Deogharkar, Akash, Mody, R, Chinnaiyan, A, Kurokawa, R, Pratt, D, Yadav, VN, Grill, J, Kline, C, Mueller, S, Resnick, A, Nazarian, J, Chung, Chan, Allen, JE, Odia, Y, Gardner, SL, Koschmann, C, Tarapore, Rohinton S.

Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas

- Przystal, Justyna M., Cosentino, Chiara Cianciolo, Biery, Matt C., Myers, Carrie, Olson, James M., Panditharatna, Eshini, Kritzer, Bettina, Mourabit, Sulayaman, Vitanza, Nicholas A., Filbin, Mariella G., de Iuliis, Geoffry N., Dun, Matthew D., Yadavilli, Sridevi, Koschmann, C, Cain, JE, Grotzer, MA, Waszak, SM, Mueller, S, Nazarian, J, Zhang, Jie, Laternser, Sandra, Bonner, Erin R., Prasad, Rachna, Dawood, Adam A., Lobeto, Nina, Chong, Wai Chin

The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies

- Persson, Mika L., Douglas, Alicia M., Alvaro, Frank, Faridi, Pouya, Larsen, Martin R., Alonso, Marta M., Vitanza, Nicholas A., Dun, Matthew D.